BioSpace News Archive

Drug Development

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. today announced it has completed enrollment in the second cohort of patients in the ongoing Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.

September 13, 2023

·

5 min read

Business

Volition Hosts Key Opinion Leader Roundtable on Sepsis Management

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, is hosting a Key Opinion Leader (“KOL”) roundtable discussion in Athens this weekend, bringing together world-renowned experts in sepsis.

September 13, 2023

·

6 min read

Genetown

CereVasc eShunt® System Study Data Presented at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Marseille

CereVasc, Inc. announced that data from a clinical study conducted in Argentina, examining the use of its eShunt System to treat communicating hydrocephalus (CH), was recently presented at the ESMINT Congress in Marseille.

September 13, 2023

·

4 min read

Business

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

Q32 Bio and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata.

September 13, 2023

·

7 min read

Pharm Country

HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE

Harmony Biosciences Holdings, Inc. today announced that Harmony’s management team will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference.

September 13, 2023

·

1 min read

Genetown

Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO ® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease.

September 13, 2023

·

14 min read

Genetown

Akili Announces Business Transformation, Focusing on Non-prescription Model

Akili, Inc., a leading digital medicine company, announced its strategic plan to transition from a prescription to a non-prescription business model.

September 13, 2023

·

15 min read

Drug Development

RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress

Lineage Cell Therapeutics, Inc. today announced that the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure from a Phase 1/2a clinical study of RG6501.

September 13, 2023

·

7 min read

Aytu BioPharma to Present at LD Micro Main Event XVI Conference

Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the LD Micro Main Event XVI Conference, being held on October 3-5, 2023, at Luxe Sunset Boulevard Hotel in Los Angeles.

September 13, 2023

·

1 min read

Biotech Bay

Biotricity Unveils a New Digital Presence, Highlighting its Expanding Technology Portfolio and Cutting-Edge Innovations

Biotricity Inc. announced today the official launch a new digital presence that illustrates more completely the depth of Biotricity technologies and solutions.

September 13, 2023

·

7 min read